Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
You can edit or delete your press release Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Projected to Grow at 16.3% CAGR, Reaching $28.3 Billion by 2029 here News-ID: 4281784 Views: More Releases from The Business Research Company Top Players and Competitive Dynamics in the Influenza Drug Market The influenza drug sector is poised for impressive expansion as advancements in treatment technologies and public health initiatives gain momentum
Improves the look of dullness and tired eyes
This epigenetic regulation may represent another avenue for hepatoprotective effects
They provide protection for your heart, kidneys, and brain while helping with metabolic health
That's so funny
Key Developments March 2026: Structure Therapeutics reported positive Phase II ACCESS II results for aleniglipron, its once-daily oral small-molecule GLP-1 receptor agonist, showing placebo-adjusted mean weight loss of up to 16.3% at 44 weeks in obesity patients
US$ 22.51
US$ 26.61
US$ 25.33
